益生菌和美沙拉嗪治疗炎症性肠病的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the efficacy and safety of Probiotics and Mesalazine in the treatment of inflammatory bowel disease.MethodsA total of 86 cases of inflammatory bowel disease patients treated in our hospital from August 2015 to December 2017 were selected as subjects.The patientswere divided into two groups according to the admission order,and each group was 43 cases.The patients in control group were given Mesalazine,the patients in the observation group were treated with Methalazine and Probiotics.The total effective rate,the incidence of adverse reaction,severity of of adverse reactions,the levels of inflammatory factors(Tumor necrosis factor-α [TNF-α],interleukin-6[IL-6]and interferon-γ [IFN-γ])and intestinal barrier function index(urine lactulose/mannitolrate[L/M])were compared between the two groups.ResultsAfter 8 weeks of treatment,the total effective rate of treatment in the observation group was higher than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups during the treatment(P＞0.05).There was no significant difference in the severity of adverse reactions between the two groups(P＞0.05).After 8 weeks of treatment,the levels of TNF-α,IL-6 and IFN-γ in the observation group were lower than those of the control group,the differenceswere statistically significant(P＜0.05).The level of L/M in the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).ConclusionProbiotics combined with Mesalazine is effective in treating inflammatory bowel disease,which can improve intestinal barrier function,relieve inflammatory reaction,shorten treatment course,and with high safety.It isworth promoting.

Key words： Probiotics Mesalazine Inflammatory bowel disease Adversereaction Iintestinal barrier function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Hong-wei
	ZENG Jing-ke

Cite this article:

ZHANG Hong-wei,ZENG Jing-ke. Effect of Probiotics and M esalazine in the treatment of inflammatory bowel disease[J]. 中国当代医药, 2018, 25(16): 174-176转186.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I16/174

[8]	王雪艳，解淑萍，索智敏，等.布地奈德和美沙拉嗪对活动期炎症性肠病的疗效及作用机制研究[J].中国临床药理学杂志，2015，31（16）：1594-1596.
[4]	钟雄利，谭小燕，许超贵，等.炎症性肠病治疗中益生菌联合美沙拉嗪的应用效果探讨[J].中国实用医药，2015，10（14）：189-190.
[5]	秦娟秀，马硝惟，戴颖欣，等.炎症性肠病患者中艰难梭菌感染的分子流行特征[J].中国感染与化疗杂志，2016，16（6）：761-766.
[6]	王雪艳，解淑萍，索智敏，等.布地奈德和美沙拉嗪对活动期炎症性肠病的疗效及作用机制研究[J].中国临床药理学杂志，2015，31（16）：1594-1596.
[7]	晏廷亮，张帆，崔道林，等.美沙拉嗪联合益生菌对炎症性肠病大鼠模型血清IL-6、TNF-α和IFN-γ含量的影响[J].中国医学创新，2014，11（20）：13-14.
[1]	Merkley SA，Beaulieu DB，Horst S，et al.Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments[J].Gastroenterology，2014，146（5）：240.
[2]	Ashton，JJ，Coelho T，EnnisS，etal.Presentingphenotypeofpaediatric inflammatory bowel disease inWessex，Southern England 2010～2013[J].Actapaediatrica，2015，104（8）：831-837.
[3]	Kvasnovsky CL，Aujla U，Bjarnason I.Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease[J].Scand JGastroenterol，2015，50（3）：255-263.
[9]	陈娟，康靖东，侯凤杰，等.美沙拉嗪联合灌洗剂治疗溃疡性结肠炎的疗效观察[J].中华损伤与修复杂志（电子版），2014，9（5）：519-520.
[10]	尹明明，施嫣红，沈蓉蓉，等.益生菌改善炎症性肠病患者的临床疗效和肠屏障功能观察[J].中国微生态学杂志，2017，29（4）：427-430.
[11]	杨凤英，鲁鹏，蓝晓慧，等.益生菌在炎症性肠病治疗中的研究进展[J].中国微生态学杂志，2014，26（6）：735-739.
[12]	王霄腾，戴金锋，吕宾，等.益生菌对炎症性肠病诱导和维持缓解疗效的 meta分析[J].胃肠病学，2015，20（1）：29-35.
[13]	梅晨雪，王恩铭扬，林连捷，等.益生菌治疗炎症性肠病与幽门螺杆菌阳性率的相关性分析[J].实用药物与临床，2017，20（6）：648-652.
[14]	王晖，黄海涛，梁三红，等.益气健脾法联合益生菌对炎症性肠病患者血清炎症因子的影响[J].中华全科医学，2017，15（9）：1574-1576.
[15]	李向阳.美沙拉嗪与益生菌治疗炎症性肠病的效果观察[J].临床医学，2015，35（11）：53-54.